Protagen Hopes to Have Diagnostics Deal Inked by End of 2010, Says CEO
June 30, 2009
Protagen Hopes to Have Diagnostics Deal Inked by End of 2010, Says CEO
CEO Stefan Muellner told BioArray News last week that Protagen has shifted its business strategy from developing tests on its UniArray protein chip platform to discovering panels of biomarkers that can later be brought to market by bigger firms.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010 / ProteoMonitor - Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers
April 22, 2011 / ProteoMonitor - Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 1, 2011 / ProteoMonitor - Protagen Raises $5.3M to Fund Platform Expansion, Dx Programs
August 4, 2009 / BioArray News - SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News